Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and now represent the mainstay of treatment for many tumor types, including triple-negative breast cancer and two agnostic registrations. However, despite impressive durable responses suggestive of an even curative potential in some cases, most patients receiving ICIs do not derive a substantial benefit, highlighting the need for more precise patient selection and stratification. The identification of predictive biomarkers of response to ICIs may play a pivotal role in optimizing the therapeutic use of such compounds. In this Review, we describe the current landscape of tissue and blood biomarkers that could serve as predictive factors for ICI treatment in breast cancer. The integration of these biomarkers in a “holistic” perspective aimed at developing comprehensive panels of multiple predictive factors will be a major step forward towards precision immune-oncology.

Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer / Licata, L.; Mariani, M.; Rossari, F.; Viale, G.; Notini, G.; Naldini, M. M.; Bosi, C.; Piras, M.; Dugo, M.; Bianchini, G.. - In: THE BREAST. - ISSN 0960-9776. - 69:(2023), pp. 330-341. [10.1016/j.breast.2023.03.014]

Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer

Mariani M.
Secondo
;
Rossari F.;Notini G.;Naldini M. M.;Bosi C.;Bianchini G.
Ultimo
2023-01-01

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and now represent the mainstay of treatment for many tumor types, including triple-negative breast cancer and two agnostic registrations. However, despite impressive durable responses suggestive of an even curative potential in some cases, most patients receiving ICIs do not derive a substantial benefit, highlighting the need for more precise patient selection and stratification. The identification of predictive biomarkers of response to ICIs may play a pivotal role in optimizing the therapeutic use of such compounds. In this Review, we describe the current landscape of tissue and blood biomarkers that could serve as predictive factors for ICI treatment in breast cancer. The integration of these biomarkers in a “holistic” perspective aimed at developing comprehensive panels of multiple predictive factors will be a major step forward towards precision immune-oncology.
2023
Breast cancer
Immune checkpoint inhibitors
Predictive biomarkers
File in questo prodotto:
File Dimensione Formato  
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer.pdf

accesso aperto

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Creative commons
Dimensione 5.01 MB
Formato Adobe PDF
5.01 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/161316
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact